Constantine Moschonas, MD
Neurology · Scottsdale, AZNPI 1205965019
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,227 of the $3,227 with a category attached, or 69.0%. 24 manufacturers reported payments, led by Amnio Technology, LLC at 34.7% of the total. Reporting peaked in 2024 at $1,177 and has fallen 77.4% since, to $266 in 2025.
Across 51 payments — averaging $63.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amnio Technology, LLC$1K
- Pinnacle Transplant Technologies, LLC$763
- AbbVie$311
- Novartis$174
- Argenx US, Inc.$151
- Biogen$96
- plus $612 from 18 others
Across 16 payments — averaging $13,876 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$128K
- Genentech, Inc.$46K
- Sanofi$24K
- Eisai Inc.$18K
- Biogen$5K
What the payments were for
- Food & beverage$2,22769%
- Gifts$1,00031%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amnio Technology, LLC | 2 | $1,119 |
| Pinnacle Transplant Technologies, LLC | 1 | $763 |
| AbbVie | 12 | $311 |
| Novartis | 3 | $174 |
| Argenx US, Inc. | 3 | $151 |
| Biogen | 1 | $96 |
| Teva Pharmaceuticals USA, Inc. | 3 | $90 |
| Bristol Myers Squibb | 3 | $55 |
| Eisai Inc. | 2 | $48 |
| Lilly USA, LLC | 3 | $48 |
| MDD US Operations, LLC | 1 | $47 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| Pfizer | 2 | $34 |
| Neurelis, Inc. | 2 | $27 |
| AstraZeneca | 1 | $25 |
| UCB, Inc. | 1 | $24 |
| Aprecia Pharmaceuticals, LLC | 1 | $22 |
| Corium, LLC | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,227 in reported general payments places this provider in the 55th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BetaseronInterferon Beta-1b | 13 | $126,855 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $61,507 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $33,455 |
| GlatopaGlatiramer Acetate | 21 | $31,146 |
| BotoxOnabotulinumtoxina | 16 | $17,120 |
| OxycontinOxycodone Hcl | 11 | $10,922 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,057 |
| EliquisApixaban | 12 | $7,152 |
| Galantamine ErGalantamine Hbr | 59 | $6,720 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 64 | $4,718 |
| Gabapentin | 153 | $4,422 |
| Carbamazepine ErCarbamazepine | 30 | $3,820 |
| Levetiracetam | 83 | $3,797 |
| LyricaPregabalin | 12 | $3,693 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 108 | $3,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Eliquis, Lyrica | $34 | $72,35336 claims |
| AbbVieBotox | $311 | $17,12016 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $43 | $2,56435 claims |
| Upsher-smith Laboratories LLCTopiramate | $17 | $1,12192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 388 neurology providers in Arizona.
Other neurology in Scottsdale
- Nida LaurinScottsdale$969K
- Dean WingerchukScottsdale$324K
- Amaal StarlingScottsdale$315K
- Virgilio Gerald EvidenteScottsdale$231K
- Brent GoodmanScottsdale$198K
- David SapersteinScottsdale$135K
- Maciej MrugalaScottsdale$97K
- Charles AdlerScottsdale$74K
- Jill RauScottsdale$59K
- Shyamal MehtaScottsdale$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.